Fingolimod Augments Monomethylfumarate Killing of GBM Cells
Previously we demonstrated that the multiple sclerosis drug dimethyl fumarate (DMF) and its plasma breakdown product MMF could interact with chemotherapeutic agents to kill both GBM cells and activated microglia. The trial NCT02337426 demonstrated the safety of DMF in newly diagnosed GBM patients wh...
Main Authors: | Paul Dent, Laurence Booth, Jane L. Roberts, Andrew Poklepovic, John F. Hancock |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00022/full |
Similar Items
-
A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles
by: Francisco Javier García-Fernández, et al.
Published: (2021-02-01) -
Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer’s Disease
by: Pablo Bascuñana, et al.
Published: (2023-02-01) -
Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models
by: Tristan Rupp, et al.
Published: (2022-07-01) -
Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis
by: María José Zarzuelo Romero, et al.
Published: (2021-04-01) -
USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS
by: V. R. Mkrtchyan, et al.
Published: (2016-12-01)